Chen, Guan-JhouGuan-JhouChenHSIN-YUN SUNSUI-YUAN CHANGARISTINE CHENGYU-SHAN HUANGYI-CHIA HUANGSu, Yi-ChingYi-ChingSuLiu, Wen-ChunWen-ChunLiuHung, Chien-ChingChien-ChingHungCHIEN-CHING HUNG2021-03-172021-03-172021-02-1312019712https://scholars.lib.ntu.edu.tw/handle/123456789/553005The impact of very low-level viremia (VLLV) and low-level viremia (LLV) are rarely investigated among people living with HIV (PLWH) receiving dolutegravir- vs protease inhibitor (PI)-based antiretroviral therapy (ART).Genetic barrier; Integrase strand transfer inhibitor; Nucleoside reverse transcriptase inhibitor; Resistance-associated mutation; Virological failure[SDGs]SDG3abacavir; atazanavir; darunavir; dolutegravir; lamivudine; lopinavir; nonnucleoside reverse transcriptase inhibitor; proteinase inhibitor; RNA directed DNA polymerase inhibitor; tenofovir disoproxil; virus RNA; zidovudine; antiretrovirus agent; dolutegravir; fused heterocyclic rings; integrase inhibitor; oxazine derivative; piperazine derivative; proteinase inhibitor; pyridone derivative; adult; antiretroviral therapy; antiviral resistance; Article; CD4 lymphocyte count; cohort analysis; controlled study; drug substitution; drug withdrawal; female; follow up; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; human tissue; incidence; major clinical study; male; metabolic syndrome X; observational study; retrospective study; risk factor; treatment duration; unspecified side effect; viremia; virus load; clinical trial; Human immunodeficiency virus infection; middle aged; viremia; virology; virus load; Adult; Anti-Retroviral Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Incidence; Male; Middle Aged; Oxazines; Piperazines; Protease Inhibitors; Pyridones; Viral Load; Viremiajournal article10.1016/j.ijid.2021.02.045335923392-s2.0-85101976148https://api.elsevier.com/content/abstract/scopus_id/85101976148